Karen Ruckman
Associate Professor, Strategy / Innovation and Entrepreneurship
Area Coordinator, Strategy
Burnaby
Room: WMC 4313
Phone: 778.782.5374
Email: ruckman@sfu.ca
Curriculum Vitae: View
Credentials
Ph.D. (University of British Columbia); M.A. (Queen's); B.Sc., Honours (University of Alberta)Biography
Karen Ruckman, an Associate Professor in Strategy, joined the Beedie School of Business in 2004 from Concordia University in Montreal where she was an Assistant Professor in the John Molson School of Business. Her specialization is firm-level strategic activities with a special focus on technology transfer, licensing and imitation. Her industry focus includes biotechnology and pharmaceuticals, information systems and financial goods.
Research Interests
Technology management, R&D strategy, imitation strategy, acquisition motivation, biotechnology, software, licensing in the biotech sector, business level strategy in the Indian IT sector.Selected Publications
articles and reports
Ruckman, K., & Blettner, D. (2022). What role does generic strategy play in how managers adapt their aspirations in response to performance feedback? Journal of Strategy and Management, 15(4), 718-744. http://doi.org/10.1108/JSMA-01-2021-0018
McCarthy, I. P., & Ruckman, K. (2017). Licensing speed: Its determinants and payoffs. Journal of Engineering and Technology Management - JET-M, 46, 52-66. http://doi.org/10.1016/j.jengtecman.2017.11.002
Ruckman, K., & McCarthy, I. (2017). Why do some patents get licensed while others do not? Industrial and Corporate Change, 26(4), 667-688. http://doi.org/10.1093/icc/dtw046
Ruckman, K., Saraf, N., & Sambamurthy, V. (2015). Market positioning by IT service vendors through imitation. Information Systems Research, 26(1), 100-126. http://doi.org/10.1287/isre.2014.0555
Ruckman, K. (2009). Technology sourcing acquisitions: What they mean for innovation potential. Journal of Strategy and Management, 2(1), 56-75. http://doi.org/10.1108/17554250910948703
Ruckman, K. (2008). Externally sourcing research through acquisition: Should it supplement or substitute for internal research? Industry and Innovation, 15(6), 627-645. http://doi.org/10.1080/13662710802550976
Ruckman, K. E. (2005). Technology sourcing through acquisitions: Evidence from the U.S. Drug industry. Journal of International Business Studies, 36(1), 89-103.
Ruckman, K. (2005). Technology sourcing through acquisitions: Evidence from the US drug industry. Journal of International Business Studies, 36(1), 89-103. http://doi.org/10.1057/palgrave.jibs.8400110
Ruckman, K. E. (2004). Entry mode into a foreign market: The case of U.S. Mutual funds in Canada. Journal of International Economics, 62(2), 417-432.
Ruckman, K. E. (2003). Expense ratios of North American mutual funds. Canadian Journal of Economics, 36(1), 192-223. http://doi.org/10.1111/1540-5982.00010
Related Teaching Material
Ruckman, K. (2007). Acquiring Biopharmaceutical Research: Is Market Approval a Deal Breaker? In Cooper, C. L., & Finkelstein, S. (Eds.), Advances in Mergers and Acquisitions Volume 6 (pp. 171-187). Elsevier Ltd (UK). http://doi.org/10.1016/S1479-361X(07)06008-5